Wellington Management Group’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Wellington Management Group’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-32,976	Closed	-$3.54M	–	2080
2023 Q1	$3.54M	Sell	32,976 -418	-1%	-$48.1K	﹤0.01%	1365
2022 Q4	$3.67M	Buy	33,394 +14,704	+79%	+$953K	﹤0.01%	1357
2022 Q3	$1.1M	Buy	+18,690	New	+$855K	﹤0.01%	1634
2021 Q2	–	Sell	-150,193	Closed	-$2.74M	–	2303
2021 Q1	$2.74M	Buy	+150,193	New	+$3.1M	﹤0.01%	1562

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Wellington Management Group's RXDX Position: Q2 2023 in Review

Wellington Management Group sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 32,976 shares — an estimated $3.54M sold.

Wellington Management Group first reported a position in RXDX in Q1 2021 and held it in 4 quarters. The position peaked at $3.67M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Wellington Management Group reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Wellington Management Group sold 32,976 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $3.54M.
Wellington Management Group first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
Wellington Management Group's Prometheus Biosciences, Inc. Common Stock position peaked at $3.67M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Wellington Management Group's 13F filing for Q2 2023, filed 14 Aug 2023.